artnet AG: Artnet Publishes Annual Report Showing Accelerated Growth and Increased Revenue
4.5.2022 18:29:00 EEST | Business Wire | Press release
Artnet AG, the leading platform for art market data and media, and the global marketplace for fine art, today published its Annual Report for the financial year 2021. As reflected in the report, Artnet accelerated its growth, with total revenue increasing 14% to 24,6 Million USD. In line with expectations, the Company recorded net income of -887k USD in 2021 as a result of strategic investments in key hires and product development. During the 2021 financial year, Artnet reached significant milestones, growing its market share and customer base. The company also streamlined its segmentation into three core product areas: Data, Marketplace, and Media. "2021 set the foundation for accelerated growth at Artnet as the art industry continues its shift online. Over the coming years we will focus on unlocking the synergies that exist within our diversified business model in order to provide the platform for its digital future.” commented Artnet CEO Jacob Pabst.
Within the Media segment, Artnet experienced record-breaking growth, with a 40% increase in revenue and a 27% increase in traffic leading to over 100 million pageviews on Artnet News. The introduction of Artnet News Pro in May 2021 provides the media segment with an additional revenue stream through a partial-paywall subscription model targeting Artnet’s most engaged readership. In total Artnet achieved 30% traffic growth across the platform, reaching over 200 Million pageviews and making it the most visited Fine Art platform globally.
Within the Marketplace segment, Artnet Auctions achieved robust results during the financial year 2021, cementing and building upon the 25% record revenue growth of 2020. Artnet Auctions' average transaction value (ATV) increased 13% YoY to $16,100, while fee-based revenue increased 6% year-over-year to 5.1 million USD. Artnet, therefore, is the fourth largest auction house for online fine art sales behind Sotheby's, Christie's and Phillips. The introduction of ArtNFT, a curated web-3 enabled, ethereum-compatible NFT platform generated over 500k USD in sales during the inaugural sale in Q4 of 2021.
The Data segment reached the historic milestone of 15 million auction results. Data inputs increased 23.5% YoY, and Artnet’s Data continues to drive decision making as the critical pricing tool for the industry. In Q2 of 2022, Artnet will relaunch the Price Database following a complete rebuild that will feature a revamped user experience, mobile first design, and a new API enabled data architecture.
“Artnet’s Data, Media, and Marketplace segments are unique in the market, with each representing a critical tool for the global art industry,” said Artnet CSO Albert Neuendorf. "These three pillars provide the foundation for a fully integrated data-driven online transactional ecosystem, and the renewed Price Database is a key step to realizing that future.” Along with the complete rebuild of the Price Database there are important additional improvements which will already have an effect on revenues in 2022. A unified navigation, a full revamp of Artnet News, and important key page redesigns will significantly increase traffic and engagement.
In 2020, Artnet adopted an ESG (Environmental, Social, Corporate Governance) strategy, defined key areas of responsibility, and set specific goals to be implemented by 2025. The Annual Report 2021 includes Artnet’s audited 2021 ESG report. By reporting on ESG initiatives, Artnet pursues its principle of spearheading positive change and sustainable business practices in the art market. The annual report for the financial year 2021 is available at artnet.com/investor-relations/annual-reports/
Further Investor-relations related news and publications can be found here: http://www.artnet.com/investor-relations/
About ArtneArtnet has an unparalleled 55 million users annually, making it the largest global platform for fine art. Founded in 1989, Artnet has revolutionized the way people discover, research, and collect art today. Artnet’s Data provides mission-critical resources for the art industry, encompassing more than 15 million auction results and AI- and ML-driven analytics, further driving transparency and insight into the art market. Artnet’s marketplace connects leading galleries and auction houses with its global audience, offering a curated selection of over 250,000 artworks for sale worldwide. Artnet Auctions, the pioneering online-only auction platform, offers unprecedented reach, liquidity, and efficiency for buyers and sellers. Artnet News covers the events, trends, and people shaping the global art market with up-to-the-minute analysis and expert commentary. It is the single most-read news publication in the fine art industry, with a rapidly growing, dedicated audience. Together, Artnet’s broad synergistic product offering provides a comprehensive ecosystem that drives and informs the modern art market.
Artnet AG is listed in the Prime Standard of the Frankfurt Stock Exchange, the segment with the highest transparency standards. The majority of operations are headquartered in New York at its wholly-owned subsidiary, Artnet Worldwide Corporation, a New York based entity founded in 1989. Artnet Worldwide Corp. owns a London based subsidiary, Artnet UK Ltd.
ISIN: DE000A1K0375
LEI: 391200SHGPEDTRIC0X31
Additional features: File: https://eqs-cockpit.com/c/fncls.ssp?u=74f4925c4cd5f6ba2fadca3260a8298b
File description: Artnet Annual Report 2021
| Language: | English |
| Company: | artnet |
| AG Oranienstraße 164 | |
|
10969 |
|
| Berlin | |
| Germany | |
| Phone: | +49 (0)30 20 91 78 -0 |
| Fax: | +49 (0)30 20 91 78 -29 |
| E-mail: | info@artnet.de |
| Internet: | www.artnet.de |
| ISIN: | DE000A1K0375 |
| WKN: | A1K037 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, |
| Dusseldorf, Stuttgart, Tradegate Exchange |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005849/en/
Contact information
Sophie Neuendorf
sneuendorf@artnet.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 09:03:00 EEST | Press release
Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial network that connects banks, telcos, payment and liquidity providers to enable settlement across international markets. Fasset will also increase investment in agentic AI-enabled systems supporting corridor banking, stablecoin settlement and tokenized asset infrastructure. After raising Series B in May, Fasset has now raised a total of $119 million in 2026. The financing marks Fasset’s entry into the glob
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 08:11:00 EEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 02:01:00 EEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom